Next Article in Journal
Shot-Gun Proteomic Analysis on Roots of Arabidopsis pldα1 Mutants Suggesting the Involvement of PLDα1 in Mitochondrial Protein Import, Vesicular Trafficking and Glucosinolate Biosynthesis
Previous Article in Journal
The Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives
Previous Article in Special Issue
The Role of Physical Stimuli on Calcium Channels in Chondrogenic Differentiation of Mesenchymal Stem Cells
Open AccessReview

Anabolic Therapies in Osteoporosis and Bone Regeneration

1
Center for Musculoskeletal Surgery, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany
2
Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany
3
Berlin Institute of Health, 13353 Berlin, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(1), 83; https://doi.org/10.3390/ijms20010083
Received: 16 November 2018 / Revised: 9 December 2018 / Accepted: 18 December 2018 / Published: 26 December 2018
(This article belongs to the Special Issue Biological Basis of Musculoskeletal Regeneration)
Osteoporosis represents the most common bone disease worldwide and results in a significantly increased fracture risk. Extrinsic and intrinsic factors implicated in the development of osteoporosis are also associated with delayed fracture healing and impaired bone regeneration. Based on a steadily increasing life expectancy in modern societies, the global implications of osteoporosis and impaired bone healing are substantial. Research in the last decades has revealed several molecular pathways that stimulate bone formation and could be targeted to treat both osteoporosis and impaired fracture healing. The identification and development of therapeutic approaches modulating bone formation, rather than bone resorption, fulfils an essential clinical need, as treatment options for reversing bone loss and promoting bone regeneration are limited. This review focuses on currently available and future approaches that may have the potential to achieve these aims. View Full-Text
Keywords: osteoporosis; anabolic therapy; bone regeneration; parathyroid hormone; sclerostin; romosozumab; denosumab osteoporosis; anabolic therapy; bone regeneration; parathyroid hormone; sclerostin; romosozumab; denosumab
Show Figures

Figure 1

MDPI and ACS Style

Russow, G.; Jahn, D.; Appelt, J.; Märdian, S.; Tsitsilonis, S.; Keller, J. Anabolic Therapies in Osteoporosis and Bone Regeneration. Int. J. Mol. Sci. 2019, 20, 83.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop